The Treatment of severe aortic stenosis has experienced a significant revolution with TAVR, especially in high and intermediate risk patients, and it is now extending to low risk patients. In the US, nearly half of patients under 64 are being treated with TAVR. One of the fundamental questions that still remains unanswered revolves around deviceref="https://solaci.org/en/2024/02/14/tavr-in-low-risk-patients-10-year-evolution/" title="Read more" >...
Tricuspid regurgitation has become increasingly common, and current pharmacological treatment options are limited. In turn, surgery, which is a complex alternative, carries considerable rates of complications and mortality. In response to this issue, various percutaneous systems are being developed, such as edge-to-edge treatment, percutaneous annuloplasty, and caval valve implantation (CAVI), among others. In the analysisref="https://solaci.org/en/2024/01/18/tricvalve-12-month-evolution/" title="Read more" >...
Severe aortic stenosis due to a bicuspid aortic valve (BAV) is uncommon, especially in individuals under 65 years of age. While there are usually no significant differences according to the type of valve when it comes to surgery, with transcatheter aortic valve replacement (TAVR) some may arise. TAVR has seen significant advancements in the treatmentref="https://solaci.org/en/2024/01/12/evolution-of-bicuspid-valves-at-12-months/" title="Read more" >...
This register included 42,887 patients receiving FFR or iFR to assess moderate lesions, and 80% of them underwent FFR. Population characteristics were similar, except that the iFR group had more women, with more diabetes, MI, stroke and chronic obstructive pulmonary disease (COPD). Primary end point was a composite of all cause death, MI and unplannedref="https://solaci.org/en/2023/10/30/tct-2023-swedeheart-evolution-at-5-years/" title="Read more" >...
In recent years, there has been a steady increase in the use of transcatheter aortic valve replacement (TAVR) in younger patients, with an average age of 74 years, as observed in US medical records. This trend goes alongside encouraging durability results, as demonstrated in the 10-year NOTION study, where structural valve degeneration (SVD) with first-generationref="https://solaci.org/en/2023/10/27/tct-2023-evolut-low-risk-4-year-follow-up/" title="Read more" >...
In the context of TAVR, one of the current challenges is the need for permanent pacemaker implantation (PPM), especially when using self-expanding valves (SEV). The information available in this regard remains controversial; while some studies suggest new PPM implantation will have no significant effect on clinical evolution, others have associated them with worse prognosis. Asref="https://solaci.org/en/2023/09/06/predictors-and-evolution-of-need-for-ppm-after-tavr-with-self-expanding-valves/" title="Read more" >...
Transcatheter aortic valve replacement (TAVR) has shown remarkable benefits and continues to advance towards lower-risk patients and younger ages. However, one of its limitations lies in the demand for a permanent pacemaker (PPM), which during TAVR early stages with self-expanding valves reached 30%. Uncertainty persists regarding the evolution of patients undergoing PPM implantation after TAVR,ref="https://solaci.org/en/2023/08/17/predictors-and-evolution-of-permanent-pacemaker-after-tavr-with-self-expanding-valves/" title="Read more" >...
Left main lesions in acute coronary syndrome (ACS) represent a major risk and, at present, the best revascularization strategy is a matter of debate. Though many studies and registries have excluded this group of patients, there is data on the pros and cons of both percutaneous coronary intervention (PCI) and cardiac artery bypass graft (CABG). ref="https://solaci.org/en/2023/06/16/5-year-evolution-of-pci-vs-cabg-in-large-randomized-studies-on-acute-and-chronic-coronary-syndrome/" title="Read more" >...
Transcatheter aortic valve replacement has shown important benefits but one of its biggest challenges is showing its safety and efficacy at followup in low risk patients. At present we have 2-year data from the Evolute Low Risk, but the we lack information at longer followup. The study looked at 3-year followup of the Evolute Lowref="https://solaci.org/en/2023/05/03/evolute-low-risk-at-3-years-promising-outcomes/" title="Read more" >...
Left main coronary artery percutaneous coronary intervention (LMCA PCI) is a treatment option that is increasingly used in our setting. One of the reasons for choosing this therapeutic strategy is the improvements in devices and techniques. However, the long-term results of LMCA PCI are not well established. The aim of this retrospective study was toref="https://solaci.org/en/2023/01/31/left-main-coronary-artery-percutaneous-coronary-intervention-evolution-and-results-over-time/" title="Read more" >...